Longeveron Inc. (LGVN)
- Previous Close
1.6700 - Open
1.6700 - Bid 1.7100 x 100
- Ask 1.8000 x 100
- Day's Range
1.6202 - 1.7899 - 52 Week Range
1.6000 - 44.0000 - Volume
291,691 - Avg. Volume
2,108,421 - Market Cap (intraday)
8.492M - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-10.2000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.05
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
longeveron.comRecent News: LGVN
Performance Overview: LGVN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LGVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LGVN
Valuation Measures
Market Cap
8.01M
Enterprise Value
4.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.12
Price/Book (mrq)
1.19
Enterprise Value/Revenue
6.62
Enterprise Value/EBITDA
-0.23
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-66.49%
Return on Equity (ttm)
-157.19%
Revenue (ttm)
709k
Net Income Avi to Common (ttm)
-22.21M
Diluted EPS (ttm)
-10.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.36M
Total Debt/Equity (mrq)
30.28%
Levered Free Cash Flow (ttm)
-11.72M